Related Experiment Video

Updated: May 10, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases

Francesca Tavano1, Orazio Palmieri, Fabio Francesco di Mola

  • 1Department of Surgery, IRCCS "Casa Sollievo Della Sofferenza" Hospital, San Giovanni Rotondo, Italy.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|July 6, 2013
PubMed
Abstract

Insights

Genetic variants in neutral endopeptidase influence inflammatory bowel disease, impacting neuroimmune interactions and clinical outcomes in patients. This highlights potential therapeutic targets for Crohn's disease and ulcerative colitis.

Area of Science:

  • Gastroenterology and Immunology
  • Neuroscience
  • Genetics

Background:

  • The substance P pathway is crucial for neuroimmune signaling in intestinal inflammation.
  • Understanding its components is key to managing inflammatory bowel disease (IBD).

Purpose of the Study:

  • To investigate mucosal expression and genetic variations of substance P, neurokinin-1 receptor, and neutral endopeptidase in IBD patients.
  • To correlate these findings with clinical sub-phenotypes.

Main Methods:

  • Quantitative reverse transcription PCR (qRT-PCR) analyzed mRNA levels in inflamed and non-inflamed colonic tissues from Crohn's disease (CD) and ulcerative colitis (UC) patients.
  • Tag single nucleotide polymorphism (tag-SNP) frequencies were determined in a large cohort of CD, UC, and control individuals.
  • Expression levels and genotype distributions were examined in relation to clinical sub-phenotypes.

Main Results:

  • All three genes were overexpressed in inflamed CD tissues. In UC, only neutral endopeptidase (NE) showed significant overexpression.
  • Smoking and perianal disease correlated with substance P and neurokinin-1 receptor levels in CD.
  • A specific NE variant (rs701109) was associated with IBD and colectomy necessity in UC.

Conclusions:

  • Genetic variations in neutral endopeptidase may influence neuroimmune interactions in intestinal inflammation.
  • These genetic factors could impact clinical sub-phenotypes in inflammatory bowel disease patients.
  • Targeting neutral endopeptidase may offer therapeutic potential for IBD management.
Keywords:
Inflammatory bowel diseaseNeurokinin-1 receptorNeutral endopeptidaseSubstance P

More Related Videos

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...